Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.53 |
| ▸ | BRD2 | P25440 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522551 | 1.00 | BRD4 (0.53) | BRD4BRD2JAK2GPR55BRD3 | |
| SCHEMBL15836981 | 0.82 | BRD4 (0.56) | BRD4BRD2GPR55BRD3CREBBP | |
| SCHEMBL31392869 | 0.79 | BRD4 (0.53) | BRD4BRD2GPR55BRD3CREBBP | |
| SCHEMBL22533011 | 0.79 | BRD4 (0.53) | BRD4BRD2GPR55BRD3CREBBP | |
| SCHEMBL15836986 | 0.79 | BRD4 (0.54) | BRD4BRD2JAK2BRD3CREBBP | |
| SCHEMBL30513243 | 0.79 | BRD4 (0.51) | BRD4BRD2JAK2BRD3CREBBP | |
| SCHEMBL17631954 | 0.79 | BRD4 (0.51) | BRD4BRD2JAK2BRD3CREBBP | |
| SCHEMBL30522586 | 0.79 | PTGS2 (0.37) | BRD4GPR55MLYCD | |
| SCHEMBL3885694 | 0.78 | BRD4 (0.66) | BRD4BRD2JAK2BRD3CREBBP | |
| SCHEMBL17807840 | 0.78 | BRD4 (0.52) | BRD4BRD2JAK2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568676-A | IL-17A modulators | 赛诺菲 | 2023-08-08 | — | — | CN | disclosed |
| CN-116547275-A | IL-17A modulators | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| EP-4157828-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157827-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2020081682-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | BRD4 168/4885BRD2 598/4885JAK2 663/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | BRD4 24/4885BRD2 20/4885JAK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.